Recommendations
| ShowHide Related Items >><< - 06:50 Today
- BioNTech sees FY23 CapEx EUR500M-EUR600M
- 06:49 Today
- BioNTech sees FY23 Covid-19 vaccine revenue ~EUR 5B
- 06:47 Today
- BioNTech expects to authorize $0.5B share repurchase program in 2023
- 03/20/23
- BioNTech, OncoC4 enter collaboration to develop, commercialize ONC-392
- 03/23/23 H.C. Wainwright
- BioNTech price target lowered to $210 from $272 at H.C. Wainwright
- 12/15/22 BofA
- BioNTech upgraded to Buy at BofA oncology pipeline opportunities
- 12/15/22 BofA
- BioNTech upgraded to Buy from Neutral at BofA
- 11/08/22 Canaccord
- BioNTech price target lowered to $191 from $200 at Canaccord
- 06:46 Today
- BioNTech reports Q4 EPS EUR 9.26 vs. EUR 12.18 last year
- 11/07/22
- BioNTech reports Q3 EPS EUR 6.98 vs. EUR 12.35 last year
- 03/21/23
- FDA moving towards authorizing second omicron booster, WSJ reports
- 01/09/23
- Moderna considering $110-$130 for COVID shot, similar to Pfizer's, WSJ says
- 10/21/22
- Pfizer expects Covid-19 vaccine price of $110-$130 per dose in U.S., WSJ report
- 10/20/22
- CDC panel says COVID shots to be added to regular vaccinations, WSJ says
- 08:57 Today
- Fly Intel: Pre-market Movers
- 03/21/23
- What You Missed On Wall Street On Tuesday
- 03/21/23
- What You Missed On Wall Street This Morning
- 12/15/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
|
Recommendations
|
BofA analyst Tazeen Ahmad… ShowHide Related Items >><< - 07:09 Today
- Amicus announces European Commission approval for Pombiliti
- 02/22/23
- Amicus reports 'positive' long-term data from Phase 3 study of AT-GAA
- 01/09/23
- Amicus announces FY23 key strategic priorities
- 12/16/22
- Amicus receives positive CHMP opinion for Pombiliti for LOPD
- 03/10/23 Stifel
- Stifel says SVB fallout 'appears limited' across firm's biotech coverage
- 01/18/23 BTIG
- Amicus price target raised to $16 from $14 at BTIG
- 09/09/22 Morgan Stanley
- Amicus initiated with an Equal Weight at Morgan Stanley
- 04/13/22 Goldman Sachs
- Amicus reinstated with a Neutral at Goldman Sachs
- 03/01/23
- Amicus sees FY23 Galafold revenue growth between 12%-17% at CER
- 03/01/23
- Amicus reports FY22 EPS (82c), consensus (77c)
- 01/09/23
- Amicus sees FY23 Galafold revenue growth 12%-17% at CER
- 01/09/23
- Amicus sees FY22 revenue $329M, consensus $326.68M
- 01/20/23
- Biotech Alert: Searches spiking for these stocks today
|
Recommendations
| ShowHide Related Items >><< - 02/13/23
- U.S. video game spending fell 5% y/y in January, says NPD
- 01/19/23
- Sony announces additional games coming to PlayStation VR2
- 01/17/23
- U.S. video game consumer spending rose 2% y/y in December, says NPD
- 12/27/22
- China stocks rising with borders set to reopen on January 8
- 01/25/23 Barclays
- Tencent price target raised to $48 from $36 at Barclays
- 01/05/23 Mizuho
- Tencent price target raised to HK$330 from HK$300 at Mizuho
- 11/02/22 Morgan Stanley
- Tencent named a 'Catalyst Driven Idea' at Morgan Stanley
- 10/28/22 Barclays
- Tencent price target lowered to $31 from $44 at Barclays
- 02/27/23
- Tencent sets up team to work on ChatGPT-style chatbot, Reuters reports
- 02/23/23
- Tencent's top risk control exec leaving amid fintech revamp, Caixin reports
- 02/21/23
- Tencent seeks to be China's exclusive seller of Meta's Quest 2, WSJ reports
- 02/17/23
- Tencent scraps plans to venture into VR hardware, Reuters reports
- 03/21/23
- What You Missed This Week in Video Games
- 03/14/23
- What You Missed This Week in Video Games
- 03/02/23
- Game On: An exclusive talk with 'Disney Illusion Island' developer Dlala Studios
- 03/01/23
- What You Missed This Week in Video Games
|
Recommendations
| ShowHide Related Items >><< - 01/12/23
- lululemon teams with Nedap to advance RFID technology across stores
- 01/09/23
- Lululemon falls 14% to $282.02 after revising Q4 guidance
- 12/08/22
- Lululemon falls 9% to $340.75 after Q3 results and guidance
- 12/08/22
- Lululemon reports Q3 SSS up 22% or 25% on constant FX basis
- 03/24/23 TD Cowen
- Lululemon price target lowered to $470 from $488 at TD Cowen
- 03/24/23 Citi
- Citi opens 'positive Catalyst Watch' on Lululemon into earnings
- 03/23/23 Goldman Sachs
- Goldman checks constructive on Lululemon 'brand heat' and traffic
- 03/23/23 Jefferies
- Jefferies says Lululemon policy change shows markdown issues
- 01/09/23
- Lululemon narrows Q4 adjusted EPS view to $4.22-$4.27 from $4.20-$4.30
- 12/08/22
- Lululemon sees FY22 EPS $9.87-$9.97, consensus $9.92
- 12/08/22
- Lululemon sees Q4 EPS $4.20-$4.30, consensus $4.30
- 12/08/22
- Lululemon reports Q3 EPS $2.00, consensus $1.97
- 09/30/22
- Peloton tells Bloomberg resolved dispute with Lululemon over athletic wear
- 09/29/22
- Peloton suit against Lululemon thrown out by court, Bloomberg reports
- 09/29/22
- Lululemon wins dismissal of patent suit by Peloton, Bloomberg reports
- 03/18/23
- Buy/Sell: Wall Street's top 10 stock calls this week
- 03/16/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 01/28/23
- Buy/Sell: Wall Street's top 10 stock calls this week
- 01/24/23
- What You Missed On Wall Street On Tuesday
- 01/24/23
- Unusually active option classes on open January 24th
- 01/04/23
- Lululemon put volume heavy and directionally bearish
- 12/21/22
- Unusually active option classes on open December 21st
- 12/12/22
- Unusually active option classes on open December 12th
|
Upgrade
| ShowHide Related Items >><< - 07:27 Today
- Parsons warded $16M U.S. Army intelligence contract
- 03/23/23
- Parsons secures $14M task order contract from DOE OCED
- 03/14/23
- Parsons to acquire IPKeys Power Partners
- 03/09/23
- Parsons awarded $18M task order for ABAD capabilities
- 01/03/23 Morgan Stanley
- Parsons downgraded to Underweight from Equal Weight at Morgan Stanley
- 12/21/22 Baird
- Baird starts Parsons at Neutral on valuation despite exposure to growth markets
- 12/21/22 Baird
- Parsons initiated with a Neutral at Baird
- 12/01/22 BofA
- Parsons downgraded to Underperform at BofA after 'strong re-rating'
- 02/15/23
- Parsons sees FY23 revenue $4.38B-$4.58B, consensus $4.47B
- 02/15/23
- Parsons reports Q4 adjusted EPS 51c, consensus 54c
- 11/02/22
- Parsons raises FY22 revenue view to $4.05B-$4.20B from $3.95B-$4.15B
- 11/02/22
- Parsons reports Q3 adjusted EPS 48c, consensus 51c
|
Hot Stocks
| ShowHide Related Items >><< - 03/22/23
- Albemarle announces lithium Mega-Flex processing facility in South Carolina
- 02/23/23
- Albemarle raises quarterly dividend to 40c per share
- 02/22/23
- Albemarle signs restructuring and investment agreements with Mineral Resources
- 01/30/23
- Albemarle launches Ketjen, a wholly owned subsidiary
- 02/06/23 UBS
- Liontown Resources initiated with a Buy at UBS
- 01/23/23 JPMorgan
- Liontown Resources upgraded to Overweight from Neutral at JPMorgan
- 12/07/22 Goldman Sachs
- Liontown Resources initiated with a Neutral at Goldman Sachs
- 03/17/23 Loop Capital
- Albemarle price target raised to $403 from $397 at Loop Capital
- 03/16/23 Deutsche Bank
- Deutsche takes 'cautious tone' on lithium stocks near term
- 03/08/23 Citi
- Tesla comments 'very bullish' for lithium industry, says Citi
- 02/21/23 Piper Sandler
- Albemarle price target raised to $330 from $310 at Piper Sandler
- 02/15/23
- Albemarle backs FY23 adjusted EPS view $26.00-$33.00, consensus $28.43
- 02/15/23
- Albemarle reports Q4 adjusted EPS $8.62, consensus $8.28
- 01/23/23
- Albemarle targets 5-year net sales CAGR 19%-21% by 2027
- 01/23/23
- Albemarle raises FY22 EPS view to $21.65-$22.05, consensus $21.03
- 10/31/22
- EU looks to resolve EV subsidy dispute with the U.S , Bloomberg says
- 10/13/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 02/15/23
- Albemarle options imply 4.2% move in share price post-earnings
- 02/03/23
- Unusually active option classes on open February 3rd
- 12/27/22
- Albemarle call volume above normal and directionally bullish
- 12/06/22
- Albemarle call volume above normal and directionally bullish
|
Hot Stocks
| ShowHide Related Items >><< - 01/13/23
- AnaptysBio board authorizes $50M stock repurchase plan
- 01/05/23
- AnaptysBio announces portfolio update, discloses $575M in cash to end 2022
- 12/02/22
- AnaptysBio, GSK announces Phase 3 RUBY trial results for JEMPERLI
- 11/08/22
- AnaptysBio 'well capitalized' to execute with over $590M in cash, says CEO
- 18:22 Today
- GSK says Phase III Ruby trial demonstrates Jemperli plus chemotherapy potential
- 03/24/23
- GSK 'respectfully disagrees' with Zantac litigation ruling in California
- 03/14/23
- GSK says MenABCWY combination vaccine candidate met all 11 primary endpoints
- 03/14/23
- GSK reports China NMPA accepts regulatory submission for Nucala
- 01/06/23 Raymond James
- AnaptysBio downgraded to Market Perform from Outperform at Raymond James
- 01/06/23 Raymond James
- AnaptysBio downgraded to Market Perform from Outperform at Raymond James
- 11/09/22 Wedbush
- AnaptysBio price target raised to $32 from $21 at Wedbush
- 11/01/22 Guggenheim
- AnaptysBio upgraded to Buy at Guggenheim on checkpoint agonist opportunity
- 03/17/23 Deutsche Bank
- GSK upgraded to Buy from Hold at Deutsche Bank
- 02/26/23 Goldman Sachs
- GSK reinstated with a Buy at Goldman Sachs
- 02/10/23 Berenberg
- GSK price target raised to 1,730 GBp from 1,580 GBp at Berenberg
- 02/02/23 JPMorgan
- GSK price target raised to 1,400 GBp from 1,350 GBp at JPMorgan
- 03/01/23
- AnaptysBio reports Q4 EPS (93c), consensus (96c)
- 11/08/22
- AnaptysBio reports Q3 EPS ($1.18), consensus (72c)
- 02/01/23
- GSK reports Q4 adjusted EPS 25.8p vs. 23.6p last year
- 11/02/22
- GSK reports Q3 adjusted EPS 46.9p, up 25% AER, 11% CER
- 03/01/23
- FDA advisers vote 12-0 that data show GSK RSV vaccine effective, Bloomberg says
- 03/01/23
- FDA advisers vote 10-2 that data show GSK RSV vaccine safe, Bloomberg reports
- 12/30/22
- GSK seeks under-appreciated biotechs 'hiding in plain sight', FT reports
- 12/24/22
- Pfizer, Moderna among vaccine makers to watch in 2023, Barron's says
- 11/03/22
- Biotech Alert: Searches spiking for these stocks today
- 12/30/22
- What You Missed On Wall Street On Friday
- 12/30/22
- What You Missed On Wall Street This Morning
- 12/16/22
- Biotech Alert: Searches spiking for these stocks today
- 12/15/22
- Biotech Alert: Searches spiking for these stocks today
- 03/24/23
- GSK Pharma put volume heavy and directionally bearish
- 03/23/23
- GSK Pharma call volume above normal and directionally bullish
- 03/15/23
- GSK Pharma call volume above normal and directionally bullish
- 03/01/23
- GSK Pharma put volume heavy and directionally bearish
|
Hot Stocks
| ShowHide Related Items >><< - $458,300.00 /
+3677.07 (+0.81%) - 03/16/23
- Berkshire Hathaway buys 7.9M shares of Occidental Petroleum for $466.68M
- 02/14/23
- Berkshire added more of top-holding Apple, Paramount in Q4
- 12/19/22
- Berkshire Hathaway announces Thomas Murphy, Jr. elected to board of directors
- 12/18/22
- Fly Intel: Top five weekend stock stories
- 03/16/23
- Berkshire Hathaway buys 7.9M shares of Occidental Petroleum for $466.68M
- 02/14/23
- Berkshire added more of top-holding Apple, Paramount in Q4
- 12/19/22
- Berkshire Hathaway announces Thomas Murphy, Jr. elected to board of directors
- 12/18/22
- Fly Intel: Top five weekend stock stories
- 03/16/23
- Berkshire Hathaway buys 7.9M shares of Occidental Petroleum for $466.68M
- 03/07/23
- 1PointFive, Houston Astros announce direct air capture carbon removal agreement
- 03/02/23
- 1PointFive announces plan to develop a carbon capture, sequestration hub
- 02/28/23
- Occidental Petroleum sees FY23 total company production 1.15-1.21Mboed
- $458,300.00 /
+3677.07 (+0.81%) - 03/20/23 Gordon Haskett
- After rumors, Gordon Haskett suggests Buffett could 'start at home' with Ally
- 02/26/23 Keefe Bruyette
- Berkshire price target lowered to $480,000 from $500,000 at Keefe Bruyette
- 02/07/23 UBS
- Berkshire can outperform given uncertain economy, says UBS
- 11/06/22 Keefe Bruyette
- Berkshire price target lowered to $495,000 from $500,000 at Keefe Bruyette
- 09/21/22 Edward Jones
- Berkshire Hathaway upgraded to Buy from Hold at Edward Jones
- 08/23/22 Gordon Haskett
- Berkshire largest Celanese holder behind Vanguard, says Gordon Haskett
- 06/23/22 Truist
- Truist ups Occidental target to 'Street high' $93, sees good odds of Buffett bid
- 05/01/22 Keefe Bruyette
- Berkshire price target lowered to $560,000 from $565,000 at Keefe Bruyette
- 08:32 Today Morgan Stanley
- Occidental Petroleum price target lowered to $62 from $71 at Morgan Stanley
- 03/17/23 Barclays
- Occidental Petroleum price target raised to $78 from $70 at Barclays
- 03/10/23 Mizuho
- Occidental Petroleum price target raised to $83 from $82 at Mizuho
- 02/22/23 Evercore ISI
- Occidental Petroleum downgraded to Underperform from In Line at Evercore ISI
- $458,300.00 /
+3677.07 (+0.81%) - 02/26/23
- Berkshire Hathaway Q4 operating earnings fall 8%, cash hoard tops $128B
- 11/05/22
- Berkshire Hathaway reports quarterly loss as operating earnings jump 20%
- 02/26/23
- Berkshire Hathaway Q4 operating earnings fall 8%, cash hoard tops $128B
- 02/25/23
- Berkshire Hathaway reports Q4 operating earnings $6.71B vs. $7.29B last year
- 11/05/22
- Berkshire Hathaway reports quarterly loss as operating earnings jump 20%
- 02/27/23
- Occidental Petroleum reports Q4 adjusted EPS $1.61, consensus $1.81
- 11/08/22
- Occidental Petroleum reports Q3 adjusted EPS $2.44, consensus $2.46
- $458,300.00 /
+3677.07 (+0.81%) - 12/17/22
- Amazon, Google among Barron's 10 favorite stocks for 2023
- 11/20/22
- JPMorgan taps Walmart exec for new health venture, Bloomberg says
- 12/17/22
- Amazon, Google among Barron's 10 favorite stocks for 2023
- 11/20/22
- JPMorgan taps Walmart exec for new health venture, Bloomberg says
- $458,300.00 /
+3677.07 (+0.81%) - 03/16/23
- Fly Intel: Pre-market Movers
- 02/27/23
- What You Missed On Wall Street On Monday
- 02/27/23
- What You Missed On Wall Street This Morning
- 11/15/22
- What You Missed On Wall Street On Tuesday
- 02/27/23
- What You Missed On Wall Street On Monday
- 02/27/23
- What You Missed On Wall Street This Morning
- 11/15/22
- What You Missed On Wall Street On Tuesday
- 11/15/22
- What You Missed On Wall Street This Morning
- 03/16/23
- Fly Intel: Pre-market Movers
- 03/13/23
- Fly Insider : Uniti Group, AutoNation among week's notable insider trades
- 02/25/23
- Buy/Sell: Wall Street's top 10 stock calls this week
- 02/22/23
- What You Missed On Wall Street On Wednesday
- 03/08/23
- Early notable gainers among liquid option names on March 8th
- 03/08/23
- Unusually active option classes on open March 8th
- 02/28/23
- Early notable gainers among liquid option names on February 28th
- 02/27/23
- Occidental Petroleum options imply 4.5% move in share price post-earnings
|
Hot Stocks
| ShowHide Related Items >><< - 03/24/23
- GSK 'respectfully disagrees' with Zantac litigation ruling in California
- 03/14/23
- GSK says MenABCWY combination vaccine candidate met all 11 primary endpoints
- 03/14/23
- GSK reports China NMPA accepts regulatory submission for Nucala
- 03/01/23
- GSK says FDA Advisory Committee supports effectiveness and safety of RSV vaccine
- 03/17/23 Deutsche Bank
- GSK upgraded to Buy from Hold at Deutsche Bank
- 02/26/23 Goldman Sachs
- GSK reinstated with a Buy at Goldman Sachs
- 02/10/23 Berenberg
- GSK price target raised to 1,730 GBp from 1,580 GBp at Berenberg
- 02/02/23 JPMorgan
- GSK price target raised to 1,400 GBp from 1,350 GBp at JPMorgan
- 02/01/23
- GSK reports Q4 adjusted EPS 25.8p vs. 23.6p last year
- 11/02/22
- GSK reports Q3 adjusted EPS 46.9p, up 25% AER, 11% CER
- 03/01/23
- FDA advisers vote 12-0 that data show GSK RSV vaccine effective, Bloomberg says
- 03/01/23
- FDA advisers vote 10-2 that data show GSK RSV vaccine safe, Bloomberg reports
- 12/30/22
- GSK seeks under-appreciated biotechs 'hiding in plain sight', FT reports
- 12/24/22
- Pfizer, Moderna among vaccine makers to watch in 2023, Barron's says
- 12/30/22
- What You Missed On Wall Street On Friday
- 12/30/22
- What You Missed On Wall Street This Morning
- 12/16/22
- Biotech Alert: Searches spiking for these stocks today
- 12/15/22
- Biotech Alert: Searches spiking for these stocks today
- 03/24/23
- GSK Pharma put volume heavy and directionally bearish
- 03/23/23
- GSK Pharma call volume above normal and directionally bullish
- 03/15/23
- GSK Pharma call volume above normal and directionally bullish
- 03/01/23
- GSK Pharma put volume heavy and directionally bearish
|
Periodicals
| ShowHide Related Items >><< - 03/24/23
- User reports indicate problems at Amazon says Downdetector
- 03/22/23
- Amazon says Fire TV surpasses 200M devices sold globally
- 03/21/23
- Amazon Web Services, Nvidia enter multi-part collaboration for AI infrastructure
- 03/21/23
- Nvidia announces availability of new products featuring H100 Tensor Core GPU
- 03/24/23 Barclays
- Meta Platforms price target raised to $270 from $260 at Barclays
- 03/21/23 Loop Capital
- Best Buy price gap relative to Amazon widens, says Loop Capital
- 03/21/23 JMP Securities
- JMP analysis of Amazon data shows Peloton position strengthening
- 03/21/23 Citi
- Citi says Amazon becoming more profitable with job cuts
- 02/02/23
- Amazon sees Q1 revenue $121B-$126B, consensus $125.11B
- 02/02/23
- Amazon reports Q4 EPS 3c with Rivian loss, consensus 17c
- 02/02/23
- Notable companies reporting after market close
- 10/27/22
- Amazon sees Q4 revenue $140B-$148B, consensus $155.15B
- 03/24/23
- Visa offered sweetened $1.4B for Pismo, Valor says
- 03/23/23
- Apple weighs bidding for English football streaming rights, Bloomberg reports
- 03/20/23
- Amazon laying off another 9,000 employees, Bloomberg reports
- 03/20/23
- FTC reviewing Amazon.com's acquisition of iRobot, Politico reports
- 03/26/23
- Box Office Battle: ‘John Wick: Chapter 4’ opens with huge $73.5M
- 03/20/23
- What You Missed On Wall Street On Monday
- 03/20/23
- What You Missed On Wall Street This Morning
- 03/20/23
- What You Missed This Week in EVs and Clean Energy
- 03/22/23
- Notable open interest changes for March 22nd
- 03/07/23
- Notable open interest changes for March 7th
- 03/03/23
- Notable open interest changes for March 3rd
- 03/03/23
- Amazon call buyer realizes 11% same-day gains
|